Referencias Bibliográficas

Tratamiento farmacológico

  Autores: Domingo Ruiz Hidalgo y Francesc Formiga Perez
1. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev. 2008;88:729-67.Free Text
 
2. Bischoff-Ferrari HA, Dawson-Hugues B, Willet WC, Staehelin HB, Bazemore MG Zee RY, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006. Free Text
 
3. Lathman NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strenght, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc 2003; 51:1219-26.
 
4. Annweiler C, Schott AM, Berrut G, Fantino B, Beauchet O. Viatmin D-related changes in physical performance: a systematic review. J Nutr Health Aging 2009; 13:893-8.
 
5. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: Bone and beyond, rationale and recommendations for supplementation. Am J Med 2009; 122:793-802.
 
6. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 2003;58A:M1002-8.
 
7. Van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioaivailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000; 85:3276-82.Free Text
 
8. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997; 82:1661-7. Free Text
 
9. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 2004; 33:548-555. Free Text
 
10. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005; 90 :1502-10. Free Text
 
11. Kenneth J, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strenght in elderly men: a meta-analysis. J Am Geriatr Soc. 2006; 54:1666-73. Free Text
 
12. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzeckov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88 :1478-85. Free Text
 
13. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D. Effects of transdermal testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010; 58:1134-43.
 
14. Valenti G, Denti L, Maggio M, Ceda G, Volpato S, Bandinelli S, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59 :466-72.
 
15. Igwebuike A, Irving BA, Bigelow ML, Short KR, McConnell JP, Nair KS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab. 2008; 93:534-8. Free Text
 
16. Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Eng J Med. 2006;355 :1647-59. Free Text
 
17. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60-to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med. 2003;163:720-7. Free Text
 
18. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age advance men and women. Clin Endocrinol (Oxf) 1998;49:421-32.
 
19. Rimbom EL, Piehl-Aulin K, Ljunghall S, Ljunggren O, Naessén T. Six months of hormone replacement therapy does not influence muscle strength in postmenopausal women. Maturitas 2002; 42 :225-31.
 
20. Kenny AM, Kleppinger A, Wang Y, Prestwood KM. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women. J Am Geriatr Soc. 2005; 53:1973-7.
 
21. Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, LaCroix AZ, et al. Postmenopausal hormone therapy and body composition-a substudy of the estrogen plus progestin trial of the Women’s Health Initiative. Am J Clin Nutr. 2005; 82:651-6. Free Text
 
22. Meeuwsen IB, Samson MM, Duursma SA, Verhaar HJ. Muscle strength and tibolone: a randomized double-blind, placebo-controlled trial. BJOG 2002;109 :77-84.
 
23. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan , et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124:708-16. Free Text
 
24. Hennessey JV, Chromiak JA, Dellaventura S, Reinert SE, Puhl J, Kiel DP, et al. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc. 2001;49:852-7.
 
25. Chu LW, Lam KS, Hu WJ, Hui SL, Chiu A, Chiu KC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab. 2001;86:1913-20. Free Text
 
26. Götherström G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Muscle strength in elderly adults with growth hormone (GH) deficiency after ten years of GH replacement. Eur J Endocrinol. 2010 May 12. [Epub ahead of print].
 
27. Blackman MR, Sorkin JD, Münzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288:2282-92. Free Text
 
28. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, Whyte M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2006; 91:477-84. Free Text
 
29. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009; 94:1991-2001. Free Text
 
30. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008; 149:601-11. Free Text
 
31. White HK, Petrie CD, Lanschulz W, MacLean D, Taylor A, Lyles K, et al. Capromorelin Study Group. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab.2009; 94:1198-2006. Free Text
 
32. Sumukadas D, Struthers AD, McMurdo ME. Sarcopenia-a potential target for Angiotensin-converting enzyme inhibition?. Gerontology 2006; 52:237-42
 
33. Onder G, Pennix BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359:926-30.
 
34. Sumukadas D, Withmam MD, Struthers AD, McMurdo ME. Effect of perindropril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007; 177 :867-74. Free Text
 
35. Cesari M, Pedone C, Incalzi RA, Pahor M. ACE-inhibition and physical function: results from the Trial of angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc. 2010;11:26-32. Free Text
 
36. Bunout D, Barrera G, de la Maza MP, Leiva L, Backhouse C, Hirsch S. Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects: A double blind trial. J Renin Angiotensin Aldosterone Syst. 2009;10:77-84.
 
37. Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel. 2008;11:487-94. 38. Solomon AM, Bouloux MG. Modifying muscle mass: the endocrine perspective. J Endocrinol. 2006;191:349-60.
 
38. Solomon AM, Bouloux MG. Modifying muscle mass: the endocrine perspective. J Endocrinol. 2006;191:349-60.
 
39. Lynch GS. Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opin Emerg Drugs 2004;9:345-61.
 

 

Páginas:   1


La información médica o de productos contenida en esta web se ofrece solamente con carácter formativo o educativo, y no pretende sustituir las opiniones y recomendaciones de los profesionales sanitarios, que son los que deben tomar las decisiones relativas a la salud teniendo en cuenta las características únicas de cada paciente.